s. pneumonia

Clinafloxacin (CI-960)(PD-127391) is a fluoroquinolone antibiotic.

Tosatoxumab (AR-301; KBSA301), a human immunoglobulin G1 monoclonal antibody, specifically targets and neutralizes S. aureus alpha-toxin (alpha-hemolysin; Hla) by binding to its N-terminal epitope. This interaction blocks the toxin's ability to form functional pore oligomers, crucial for its pathogenic activity. As a result, Tosatoxumab offers promising potential as an adjunctive passive immunotherapy alongside conventional antibiotics for S. aureus pneumonia [1] [2].

Lysionotin (Nevadensin) has expectorant, eliminating phlegm, softening effects.

Garenoxacin mesylate hydrate (Garenoxacin mesylate [USAN]) with potent antimicrobial activity, against common respiratory pathogens, including resistant strains.

Suvratoxumab (MEDI4893) is a high-affinity, long-acting humanized IgG1κ anti-α-toxin monoclonal antibody. It effectively neutralizes α-toxin, a principal virulence factor of S. aureus, enhancing survival and diminishing lung injury in an immunocompromised mouse model of pneumonia. Additionally, Suvratoxumab augments the antibacterial efficacy of Vancomycin and Linezolid [1] [2] [3].

Poly(I:C):Kanamycin (1:1) sodium is a symmetric complex combining Poly(I:C) sodium, a synthetic double-stranded RNA analog acting as a TLR3 and RIG-I/MDA5 agonist, with Kanamycin, an antibacterial agent effective against both Gram-negative and positive bacteria by inhibiting translocation and causing miscoding on the 70S ribosomal subunit. Poly(I:C) sodium serves as a potent vaccine adjuvant, bolstering innate and adaptive immunity and prompting apoptosis in cancer cells [1] [2]. Meanwhile, Kanamycin exhibits significant efficacy against Mycobacterium tuberculosis, including drug-resistant strains, and Klebsiella pneumoniae, offering valuable insights for tuberculosis and pneumonia research [3] [4] [5] [6].

Hirsutide is a cyclotetrapeptide fungal metabolite produced by the entomopathogenic fungus Hirsutella. It has antibacterial activity against C. pyogenes, S. aureus, P. aeruginosa, and K. pneumonia (MICs = 25, 13, 6, and 21 μg/cm3, respectively). Hirsutide also has antifungal activity against C. albicans, M. audouinii, A. niger, and Ganoderma (MICs = 13, 6, 25, and 6 μg/cm3, respectively).

Garenoxacin (BMS284756) is a novel oral des-fluoro(6) quinolone for the treatment of Gram-positive and Gram-negative bacterial infections.

Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU/ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens.

NSC 55655 (5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione) possesses antimicrobial and antioxidant activities and inhibits the proliferation of B. subtilis, S. aureus, K. pneumonia, E. coli, S. typhi , A. niger and C. albicans. A. niger and C. albicans, and can be used in diabetes mellitus.

Telithromycin (HMR3647) is a ketolide antibiotic to treat community acquired pneumonia of mild to moderate severity. Antibacterial Telithromycin prevents bacteria from growing, by interfering with their protein synthesis. Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain. Telithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, telithromycin strongly bind simultaneously to two domains of 23S RNA of the 50 S ribosomal subunit, where older macrolides bind strongly only to one domain and weakly to the second domain. Telithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.